CR20120177A - Nuevos compuestos de espiropiperidina y el uso farmacéutico del mismo para el tratamiento de diabetes - Google Patents

Nuevos compuestos de espiropiperidina y el uso farmacéutico del mismo para el tratamiento de diabetes

Info

Publication number
CR20120177A
CR20120177A CR20120177A CR20120177A CR20120177A CR 20120177 A CR20120177 A CR 20120177A CR 20120177 A CR20120177 A CR 20120177A CR 20120177 A CR20120177 A CR 20120177A CR 20120177 A CR20120177 A CR 20120177A
Authority
CR
Costa Rica
Prior art keywords
diabetes
spiropiperidine
treatment
same
new compounds
Prior art date
Application number
CR20120177A
Other languages
English (en)
Inventor
Chafiq Hamdouchi
Jayana Pankaj Lineswala
Pranab Maiti
Original Assignee
Lilly Co Eli
Memory Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43719548&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20120177(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli, Memory Pharm Corp filed Critical Lilly Co Eli
Publication of CR20120177A publication Critical patent/CR20120177A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto de la fórmula:o una sal del mismo farmacéuticamente aceptable así como también una composición farmacéutica, y un método para tratar diabetes.
CR20120177A 2009-10-15 2012-04-12 Nuevos compuestos de espiropiperidina y el uso farmacéutico del mismo para el tratamiento de diabetes CR20120177A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25183909P 2009-10-15 2009-10-15
US30333410P 2010-02-11 2010-02-11

Publications (1)

Publication Number Publication Date
CR20120177A true CR20120177A (es) 2012-06-06

Family

ID=43719548

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120177A CR20120177A (es) 2009-10-15 2012-04-12 Nuevos compuestos de espiropiperidina y el uso farmacéutico del mismo para el tratamiento de diabetes

Country Status (24)

Country Link
US (1) US8383642B2 (es)
EP (1) EP2488500A1 (es)
JP (1) JP2013508279A (es)
KR (1) KR20120051777A (es)
CN (1) CN102574807A (es)
AR (1) AR078522A1 (es)
AU (1) AU2010307094A1 (es)
BR (1) BR112012008889A2 (es)
CA (1) CA2777775A1 (es)
CL (1) CL2012000921A1 (es)
CO (1) CO6531458A2 (es)
CR (1) CR20120177A (es)
DO (1) DOP2012000105A (es)
EA (1) EA201270560A1 (es)
EC (1) ECSP12011799A (es)
IL (1) IL218344A0 (es)
MA (1) MA33662B1 (es)
MX (1) MX2012004420A (es)
NZ (1) NZ598972A (es)
PE (1) PE20121437A1 (es)
TN (1) TN2012000152A1 (es)
TW (1) TW201124415A (es)
WO (1) WO2011046851A1 (es)
ZA (1) ZA201202560B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2411395T3 (pl) 2009-03-23 2013-10-31 Glenmark Pharmaceuticals Sa Pochodne furopirymidynodionu jako modulatory TRPA1
EA023857B1 (ru) 2009-03-23 2016-07-29 Гленмарк Фармасеутикалс С.А. Сочлененные производные пиримидиндионов в качестве модуляторов trpa1
AR078948A1 (es) 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes
MX2012007474A (es) 2009-12-25 2012-08-01 Mochida Pharm Co Ltd Derivados de 3-hidroxi-5-arilisotiazol novedosos.
WO2012046869A1 (ja) 2010-10-08 2012-04-12 持田製薬株式会社 環状アミド誘導体
WO2012125397A2 (en) 2011-03-11 2012-09-20 Kraft Foods Global Brands Llc System and method of forming multilayer confectionery
MX2013012520A (es) 2011-04-27 2014-02-03 Mochida Pharm Co Ltd Derivado novedoso de 1-oxido de 3-hidroxi isotiazol.
JPWO2012147516A1 (ja) 2011-04-28 2014-07-28 持田製薬株式会社 環状アミド誘導体
TWI537262B (zh) 2011-08-17 2016-06-11 美國禮來大藥廠 供治療糖尿病使用之新穎１，２，３，４－四氫喹啉衍生物
WO2013139341A1 (en) * 2012-03-20 2013-09-26 Syddansk Universitet Gpr120 receptor modulators
WO2013185766A1 (en) * 2012-06-15 2013-12-19 Syddansk Universitet Gpr120 receptor modulators
CN104812748B (zh) 2012-11-16 2017-10-24 百时美施贵宝公司 二氢吡唑gpr40调节剂
KR101569522B1 (ko) * 2013-04-18 2015-11-17 현대약품 주식회사 신규한 3-(4-(벤질옥시)페닐)헥스-4-이노익 산 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
US10011609B2 (en) * 2013-11-14 2018-07-03 Cadila Healthcare Limited Heterocyclic compounds
US20150351889A1 (en) 2014-06-05 2015-12-10 Vivex Biomedical Inc. Dynamic Biometric Mesh
KR101728900B1 (ko) * 2014-10-17 2017-04-24 현대약품 주식회사 신규한 3-(4-(벤질옥시)페닐)헥스-4-이노익 산 유도체 및 다른 유효성분을 포함하는 대사성 질환의 예방 또는 치료용 복합제제
CN109666027A (zh) * 2017-10-17 2019-04-23 中国科学院上海药物研究所 一类酰胺结构的gpr40激动剂化合物及其用途
DK3737470T5 (da) 2018-01-08 2024-05-27 Celon Pharma Sa 3-phenyl-4-hexynsyrederivater som gpr40-agonister
PL3752501T3 (pl) 2018-02-13 2023-08-21 Gilead Sciences, Inc. Inhibitory pd-1/pd-l1
JP7242702B2 (ja) 2018-04-19 2023-03-20 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
KR20230159715A (ko) 2018-07-13 2023-11-21 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
KR102635333B1 (ko) 2018-10-24 2024-02-15 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト
UY39222A (es) 2020-05-19 2021-11-30 Kallyope Inc Activadores de la ampk
EP4172162A4 (en) 2020-06-26 2024-08-07 Kallyope Inc AMPK ACTIVATORS

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE413175T1 (de) * 2001-04-18 2008-11-15 Euro Celtique Sa Spiroinden- und spiroindan-verbindungen
KR20050120773A (ko) * 2003-04-04 2005-12-23 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 작용제로서의 아실화스피로피페리딘 유도체
JP2007510662A (ja) 2003-11-04 2007-04-26 エリクシアー ファーマシューティカルズ， インコーポレイテッド 治療化合物およびその使用
WO2005051890A1 (en) 2003-11-19 2005-06-09 Smithkline Beecham Corporation Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
EP1737809B1 (en) 2004-02-27 2013-09-18 Amgen, Inc Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
US7517910B2 (en) * 2004-03-30 2009-04-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
AU2006291234A1 (en) * 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
WO2008030618A1 (en) 2006-09-07 2008-03-13 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
CL2008003153A1 (es) * 2007-10-26 2009-07-24 Japan Tobacco Inc Compuestos espiro condensados, agonistas de gpr40: composicion farmaceutica que comprende a uno de los compuestos; y el uso de los compuestos en la preparacion de medicamentos para el tratamiento de la diabetes, hiperglicemia, alteracion de tolerancia a la glucosa en ayuna, entre otras.
JP2011504499A (ja) * 2007-11-21 2011-02-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ トリプターゼ阻害剤として使用するためのスピロピペリジン
AR078948A1 (es) 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes

Also Published As

Publication number Publication date
CN102574807A (zh) 2012-07-11
TN2012000152A1 (en) 2013-12-12
DOP2012000105A (es) 2013-01-31
MX2012004420A (es) 2012-05-08
EA201270560A1 (ru) 2012-09-28
US20110092531A1 (en) 2011-04-21
AR078522A1 (es) 2011-11-16
CO6531458A2 (es) 2012-09-28
ECSP12011799A (es) 2012-07-31
US8383642B2 (en) 2013-02-26
IL218344A0 (en) 2012-04-30
TW201124415A (en) 2011-07-16
EP2488500A1 (en) 2012-08-22
WO2011046851A1 (en) 2011-04-21
NZ598972A (en) 2013-06-28
JP2013508279A (ja) 2013-03-07
ZA201202560B (en) 2013-09-25
MA33662B1 (fr) 2012-10-01
KR20120051777A (ko) 2012-05-22
AU2010307094A1 (en) 2012-04-19
PE20121437A1 (es) 2012-10-26
BR112012008889A2 (pt) 2019-09-24
CA2777775A1 (en) 2011-04-21
CL2012000921A1 (es) 2012-09-14

Similar Documents

Publication Publication Date Title
CR20120177A (es) Nuevos compuestos de espiropiperidina y el uso farmacéutico del mismo para el tratamiento de diabetes
ECSP12011930A (es) Nuevos compuestos de espiropiperidina
BR112012026767A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
UY32062A (es) Inhibidores de beta-secretasa
UY32153A (es) Inhibidores de piridomidinona de pi13ka(alfa) y mtor
UY31215A1 (es) Compuestos de morfolino pirimidina, procesos para su preparacion, composiciones farmacéuticas conteniéndolos y su uso en terapia.
DOP2011000260A (es) Pirimidinas fusionadas
NI200900184A (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer.
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
DOP2014000018A (es) Nuevo derivado de 1,2,3,4-tetrahidroquinolina útil para el tratamiento de diabetes
CL2014001154A1 (es) Compuestos derivados antibioticos de 2-oxo-oxazolidin-3,5-diilo de formula i; composicion farmaceutica; uso para la prevencion o tratamiento de una infeccion bacteriana.
SG194463A1 (en) Glycoside derivatives and their uses for the treatment of diabetes
CR11684A (es) Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa
AR085616A1 (es) Composicion farmaceutica inhalable que comprende glicopirrolato, uso
CL2014002845A1 (es) Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2.
ECSP10010168A (es) Benzotiazolas como moduladores del receptor de ghrelina
AR080025A1 (es) Derivados de 8-aza-biciclo[3,2,1] oct-3-iloxi)-cromen-2-ona, utiles como inhibidores de la recaptacion del neurotransmisor monoamina
ECSP13012653A (es) COMPUESTOS DE OXAZOL[5,4-b]PIRIDIN-5-ILO Y SU USO PARA EL TRATAMIENTO DE CÁNCER
CO6382120A2 (es) Compuestos ciclopropilo
UY33806A (es) ?compuestos novedosos de imidazoquinolina, composiciones que los contienen y su uso en el tratamiento de enfermedades mediadas por tlr7?
BRPI1015983A2 (pt) composto, uso do composto, método para tratar um paciente, e, composição farmacêutica.
CL2007003806A1 (es) Compuestos derivados de n-(2h-pirazol-3-il)-amida, inhibidores del fgfr; composicion farmaceutica que comprende a dichos compuestos; su proceso de preparacion; y su uso para el tratamiento del cancer.
CO6300947A2 (es) Derivados de 6,7-dialcoxi quinazolina utiles para el tratamiento de cancer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)